Samsung Biologics

Samsung Biologics is a South Korean biotechnology firm based in Songdo, Incheon, South Korea. Samsung Group's biotech branch provides contract development and manufacturing (CDMO) services to the biopharmaceutical sector. The company's objective is to become its clients' most trusted partner in achieving a Better Life for Humanity through biomedicine. It pursues innovative solutions to build a more sustainable future and enhance the lives of millions throughout the world with creativity, enthusiasm, and unwavering dedication.

From 2011 to 2018, Samsung Biologics established three production units with a combined capacity of more than 360,000 liters, making it the world's biggest contract-based manufacturer in the biopharmaceutical industry. Since 2020, Samsung Biologics has had a research and development center in San Francisco, California.

For COVID-19 therapies, the business has collaborated with GlaxoSmithKline, Eli Lilly, and AstraZeneca.During the COVID-19 pandemic, Samsung Biologics collaborated with Moderna for fill-finish, packaging, and labeling of their mRNA vaccine, Spikevax, and Greenlight Biosciences on the manufacture of mRNA vaccine medicinal substance.

Founded: 2011

Headquarters: Icheon, South Korea

Website: https://samsungbiologics.com